Analysts have been eager to weigh in on the Healthcare sector with new ratings on Oncternal Therapeutics (ONCT – Research Report), Arcturus Therapeutics (ARCT – Research Report) and Foghorn Therapeutics (FHTX – Research Report). Oncternal Therapeutics (ONCT) In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Oncternal Therapeutics, with a price target of $7.00. The company's shares closed last Tuesday at $1.11, close to its 52-week low of $0.69. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oncternal-therapeutics-onct-arcturus-therapeutics-arct-and-foghorn-therapeutics-fhtx?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Oncternal Therapeutics.